Home > Boards > US Listed > Biotechs > iBio, Inc. (IBIO)

Where in the filings or PRs can I

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mastaflash Member Profile
 
Followed By 162
Posts 33,437
Boards Moderated 1
Alias Born 01/26/05
160x600 placeholder
iBio says successful in preclinical studies for subunit COVID-19 vaccine candidate Seeking Alpha - 7/16/2021 7:24:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/16/2021 6:04:34 AM
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate GlobeNewswire Inc. - 7/15/2021 5:10:00 PM
iBio establishes oncology drug discovery pipeline with three new antibody programs Seeking Alpha - 7/8/2021 4:23:04 PM
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs GlobeNewswire Inc. - 7/8/2021 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/9/2021 5:20:28 PM
iBio adds veteran biopharmaceutical executive to board of directors Seeking Alpha - 6/9/2021 4:44:08 PM
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink GlobeNewswire Inc. - 6/9/2021 4:30:00 PM
iBio to Present at the UBS Global Healthcare Virtual Conference GlobeNewswire Inc. - 5/19/2021 4:30:00 PM
iBio Q1 net loss widens as expenses soar year-over-year; shares fall 6% Seeking Alpha - 5/17/2021 10:08:32 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2021 7:16:10 AM
iBio revenue in-line Seeking Alpha - 5/17/2021 7:04:02 AM
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/17/2021 7:00:00 AM
iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021 GlobeNewswire Inc. - 5/10/2021 8:15:00 AM
ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action Seeking Alpha - 5/7/2021 8:57:30 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2021 4:46:04 PM
iBio shares surge on COVID-19 study update Seeking Alpha - 5/6/2021 4:42:34 PM
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program GlobeNewswire Inc. - 5/6/2021 4:15:00 PM
Regional Health Properties, Chiasma leads healthcare gainers; Cocrystal Pharma, Esperion Therapeutics among major losers Seeking Alpha - 5/5/2021 11:00:10 AM
ATVI, TEVA, AYX and LYFT among notable premarket gainers Seeking Alpha - 5/5/2021 8:24:13 AM
iBio shares surge after resolving Fraunhofer USA lawsuit Seeking Alpha - 5/4/2021 5:28:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/4/2021 5:16:26 PM
iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement GlobeNewswire Inc. - 5/4/2021 5:00:00 PM
iBio to Participate in the 33rd Annual Roth Conference GlobeNewswire Inc. - 3/9/2021 4:30:00 PM
Despite narrower fiscal Q2 2021 loss, iBio expenses grow; shares fall after hours Seeking Alpha - 2/16/2021 4:54:50 PM
mastaflash   Wednesday, 10/29/14 11:46:59 AM
Re: smitter post# 9205
Post # of 26230 
Where in the filings or PRs can I find reference to this?

The next day, a representative of iBio reportedly stated that the manufacture of experimental Ebola drug, ZMapp, would require a license from iBio. On this news, iBio's stock price increased significantly.

What is the source of this?




Some sheep are smarter than others.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences